Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionCombination of vitamin K-dependent clotting factors (Factor IX, II, X)
Molecular Target Factor IX
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsPrevent and control bleeding episodes in adult patients with hemophilia B
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today